Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
April 18th, 2008
CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial technologies that harness the body's innate ability to repair damaged cardiovascular tissue, presented data on its ECM Technology(TM) this week at the annual American College of Cardiology (ACC) Scientific Sessions in Chicago. Data demonstrated that ECM Technology(TM), in the form of an injectable emulsion, enhanced angiogenesis, increased recruitment of C-kit positive progenitor stem cells, and improved cardiac function in a rat model. The study, conducted at Emory University, used rats that were subjected to 45 minutes of...
Source: Health Business Week (2008-04-18)
|
